Alternative Name
EZH2
Methodology
Molecular
Test Description

Bi-directional sequencing of exons 3-13 and 15-18 of the EZH2 gene.

Clinical Significance

Somatic EZH2 mutations are detected in ~9% of CMML and ~6% of MDS, and are independent predictors of poor overall survival in MDS. In diffuse large B-cell lymphoma (DLBCL), mutations are present in ~22% of the germinal center B-cell-like (GCB) subtype of diffuse large B-cell lymphoma (DLBCL) but very rare in the activated B-cell-like (ABC) subtype, so mutation analysis can be useful to differentiate between the subtypes. EZH2 inhibitor therapy is an active area of clinical research. Constitutional EZH2 mutations are associated with Weaver Syndrome, characterized by overgrowth, advanced bone age, characteristic facial features, developmental delay, and mild predisposition to cancer.

Specimen Requirements
  • Peripheral blood: 5 mL in EDTA tube.
  • Bone marrow: 2 mL in EDTA tube.
Storage and Transportation

Use cold pack for transport, making sure cold pack is not in direct contact with specimen.

CPT Code(s)*
81479x1
Turnaround Time

7-10 days

Level of Service
Global

*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed.